Axcella Health’s (NASDAQ:AXLA) lock-up period is set to expire on Tuesday, November 5th. Axcella Health had issued 3,571,428 shares in its initial public offering on May 9th. The total size of the offering was $71,428,560 based on an initial share price of $20.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.
Several research analysts have issued reports on AXLA shares. ValuEngine raised shares of Axcella Health from a “hold” rating to a “buy” rating in a report on Friday, October 4th. Zacks Investment Research cut shares of Axcella Health from a “hold” rating to a “sell” rating in a report on Friday, October 18th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $22.00.
Shares of AXLA stock opened at $5.00 on Tuesday. The business has a 50 day moving average of $5.77. Axcella Health has a 52 week low of $4.79 and a 52 week high of $15.99. The company has a debt-to-equity ratio of 0.27, a current ratio of 17.42 and a quick ratio of 17.42.
Axcella Health (NASDAQ:AXLA) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.31). Equities research analysts anticipate that Axcella Health will post -3.82 EPS for the current fiscal year.
In related news, Director David R. Epstein purchased 6,941 shares of Axcella Health stock in a transaction dated Friday, August 2nd. The stock was purchased at an average cost of $7.00 per share, for a total transaction of $48,587.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Hedge funds have recently made changes to their positions in the company. Morgan Stanley bought a new stake in shares of Axcella Health in the second quarter worth approximately $56,000. Northern Trust Corp bought a new stake in shares of Axcella Health in the second quarter worth approximately $90,000. KCL Capital L.P. bought a new stake in shares of Axcella Health in the second quarter worth approximately $93,000. Tower Research Capital LLC TRC bought a new stake in Axcella Health during the second quarter valued at approximately $122,000. Finally, Vanguard Group Inc. bought a new stake in Axcella Health during the second quarter valued at approximately $499,000. Hedge funds and other institutional investors own 62.26% of the company’s stock.
About Axcella Health
There is no company description available for Axcella Health Inc
Read More: Preferred Stock
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.